(AMLX) –
-
Form ARS Amylyx Pharmaceuticals, For: Dec 31
-
Form DEFA14A Amylyx Pharmaceuticals,
-
Form DEF 14A Amylyx Pharmaceuticals, For: Jun 06
-
Form 4 Amylyx Pharmaceuticals, For: Apr 16 Filed by: FRATES JAMES M
-
Form 4 Amylyx Pharmaceuticals, For: Apr 16 Filed by: Cohen Joshua B
-
Form 4 Amylyx Pharmaceuticals, For: Apr 16 Filed by: Mazzariello Gina
-
Form 4 Amylyx Pharmaceuticals, For: Apr 16 Filed by: Klee Justin B.
-
Form 4 Amylyx Pharmaceuticals, For: Apr 16 Filed by: Bedrosian Camille L
-
Amylyx Pharmaceuticals inc. (AMLX) PT Lowered to $3 at Baird on latest AMX0035 data
-
Amylyx Pharmaceuticals inc. (AMLX) PT Lowered to $3.50 at BofA Securities
-
Form 8-K Amylyx Pharmaceuticals, For: Apr 10
-
Amylyx Pharma (AMLX) Announces Interim Data From Ongoing Phase 2 HELIOS Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome
-
Amylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Synd
-
AMLX DEADLINE TOMORROW: ROSEN, LEADING INVESTOR COUNSEL, Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important April 9 Deadline in Securities Class Action – AMLX
-
Amylyx Pharmaceuticals (AMLX) to Host Virtual Webcast to Discuss Interim Data from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on April 10, 2024
-
Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Interim Data from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on April 10, 2024
-
Amylyx Pharmaceuticals inc. (AMLX) PT Lowered to $3 at Goldman Sachs
-
Amylyx Pharmaceuticals inc. (AMLX) PT Lowered to $3 at Goldman Sachs
-
Amylyx Pharmaceuticals inc. (AMLX) PT Lowered to $4 at Deutsche Bank
-
Form 8-K Amylyx Pharmaceuticals, For: Apr 03
-
Amylyx Pharmaceuticals (AMLX) to Remove RELYVRIO/ALBRIOZA from the Market; Provides Updates on Access to Therapy, Pipeline, Corporate Restructuring, and Strategy
-
Amylyx Pharmaceuticals Announces Formal Intention to Remove RELYVRIO®/ALBRIOZA™ from the Market; Provides Updates on Access to Therapy, Pipeline, Corporate Restructuring, and Strategy
-
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Amylyx
-
AMYLYX PHARMACEUTICALS, INC. (NASDAQ: AMLX) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Amylyx
-
ROSEN, A LEADING LAW FIRM, Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important April 9 Deadline in Securities Class Action – AMLX
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against NYCB, Amylyx, Xponential, and InMode and Encourages Investors to Contact the Firm
-
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Amylyx
-
DEADLINE ALERT: Bernstein Liebhard LLP Reminds Amylyx Pharmaceuticals, Inc. Investors of Upcoming Deadline
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Cassava, NYCB, Amylyx, and InMode and Encourages Investors to Contact the Firm
-
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AMLX
-
AMYLYX PHARMACEUTICALS, INC. (NASDAQ: AMLX) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Amylyx
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Cassava, NYCB, Amylyx, and InMode and Encourages Investors to Contact the Firm
-
AMLX Class Action Alert: Robbins LLP Reminds Investors of Pending Lead Plaintiff Deadline – April 9, 2024 – in Amylyx Pharmaceuticals, Inc. Class Action
-
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Amylyx
-
Mizuho Downgrades Amylyx Pharmaceuticals inc. (AMLX) to Neutral
-
AMYLYX PHARMACEUTICALS, INC. (NASDAQ: AMLX) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Amylyx
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Cassava, NYCB, Amylyx, and InMode and Encourages Investors to Contact the Firm
-
ROSEN, LEADING INVESTOR COUNSEL, Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AMLX
-
Form 4 Amylyx Pharmaceuticals, For: Mar 14 Filed by: Zeiher Bernhardt G
-
Form 3 Amylyx Pharmaceuticals, For: Mar 14 Filed by: Zeiher Bernhardt G
-
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Amylyx
-
Form 8-K Amylyx Pharmaceuticals, For: Mar 14
-
Amylyx Pharmaceuticals (AMLX) Appoints Bernhardt Zeiher to its Board
-
Amylyx Pharmaceuticals Appoints Bernhardt Zeiher, MD, FCCP, FACP, to its Board of Directors
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against GrafTech, Instacart, Cassava, and Amylyx and Encourages Investors to Contact the Firm
-
Amylyx Pharmaceuticals inc. (AMLX) PT Lowered to $8 at H.C. Wainwright
-
Amylyx Pharmaceuticals inc. (AMLX) PT Lowered to $8 at Deutsche Bank
-
Leerink Partners Downgrades Amylyx Pharmaceuticals inc. (AMLX) to Market Perform
-
Baird Downgrades Amylyx Pharmaceuticals inc. (AMLX) to Neutral
-
Form SC 13G Amylyx Pharmaceuticals, Filed by: Panacea Innovation Ltd
Back to AMLX Stock Lookup
